Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

TECHNOLOGY LICENSING OPPORTUNITY: Platform to Accelerate Discovery of Tailored Industrial Enzymes (PAD-TIE)

Active
S-167703Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The PAD-TIE platform, developed by NREL and Los Alamos National Laboratory, is a high-throughput screening system designed to rapidly identify and optimize enzymes capable of breaking down polyethylene terephthalate (PET) plastic under industrially relevant conditions. Unlike traditional methods that test enzymes one at a time, PAD-TIE evaluates tens of thousands of enzyme variants simultaneously, measuring their activity, stability, and production efficiency in a single process, eliminating costly purification steps and reducing time-to-identification. The system operates at the optimal temperature for PET degradation and is validated in lab-scale bioreactors that mimic real-world recycling environments, enabling the conversion of plastic waste into reusable monomers without harsh chemicals or excessive energy use. With a Technology Readiness Level of 6, the platform is a fully functional prototype with all components tested, and three U.S. patents are pending, making it a mature and protected innovation ready for commercial adoption. PAD-TIE is positioned to serve a broad range of industries including plastic recycling, waste management, polymer manufacturing, and sustainable materials development. Its adaptability allows customization for different PET compositions, additives, and processing conditions, ensuring compatibility with existing infrastructure. The platform’s efficiency and scalability offer a cost-effective solution for scaling enzymatic plastic degradation at an industrial level. Los Alamos National Laboratory is seeking industry partners through exclusive or non-exclusive licensing agreements to further develop and deploy the technology, with applications spanning bioremediation, bioplastics, and closed-loop recycling systems. Interested parties must respond by October 1, 2026, and inquiries should be directed to the provided licensing contacts. The technology is available for commercialization under a non-set-aside procurement with a NAICS code of 541714, and performance will occur in Los Alamos, New Mexico.

General Info

NREL and LANL developed PAD-TIE, a high-throughput enzyme screening platform for industrial PET recycling.

Agency

Department Of Energy → Triad - DOE ContractorView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Los Alamos, NM, 87545, USA

Set-Aside

NONE

Documents

(2)

PAD-TIE Enzymatic Plastic Degradation Partnership Opportunity

PDFsources-sought

Tech Snapshot PAD-TIE Enzyme Discovery Platform July 2026

PDFtechnology-snapshot

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

1 update
Posted

special-notice

Amendment 1

Contract was updated

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Energy → Triad - DOE Contractor
Contacts2 people available
OfficeColumbus, OH, 43201, USA
Organization / Agency
Department Of Energy → Triad - DOE Contractor
View Agency Profile
Office AddressColumbus, OH, 43201, USA
Contacts
Michael Erickson
Lindsay Augustyn

Full Description

Show more

NREL and Los Alamos National Laboratory’s PAD-TIE platform is an advanced screening system designed to accelerate the discovery and optimization of enzymes that break down polyethylene terephthalate (PET), one of the most widely used plastics.


The Challenge:


Traditional enzyme development is slow and requires testing individual enzymes under controlled conditions. PAD-TIE overcomes this limitation by simultaneously screening tens of thousands of enzyme variants under industrially relevant conditions for PET degradation.


How it Works:


Unlike conventional methods, PAD-TIE evaluates enzyme efficiency, stability, and production potential in a single process, ensuring that only the most viable candidates move forward. Validated in lab-scale bioreactors that replicate industrial recycling environments, PAD-TIE supports sustainable PET recycling and upcycling, breaking plastic down into its fundamental building blocks (monomers) for reuse: without the need for harsh chemicals or energy-intensive processes.


Key Advantages:


  • Scalable High-Throughput Screening: Evaluates tens of thousands of enzyme variants simultaneously, accelerating discovery.
  • Optimized for Industrial Use: Operates at the optimal temperature for enzymatic PET degradation and high plastic processing efficiency, ensuring compatibility with existing recycling infrastructure.
  • Efficient Resource Use: Uses widely available reagents and eliminates enzyme purification in early screening, reducing material and labor costs.
  • Comprehensive Performance Assessment: Simultaneously measures enzyme activity, stability, and production efficiency, reducing failure rates.
  • Adaptable to Industry Needs: Can be optimized for various processing conditions, different PET compositions, and additives in plastic waste.

Market Applications:


PAD-TIE is designed for industry partners seeking scalable, enzyme-based solutions for plastic waste management and recycling, including:


  • Recycling & Waste Management: Enhances PET recycling by breaking plastic down into reusable monomers.
  • Bioremediation & Environmental: Supports plastic degradation in marine environments, landfills, and polluted sites.
  • Polymer Manufacturers: Enables the integration of engineered enzymes into industrial plastic processing workflows.
  • Bioplastics & Sustainable Materials: Contributes to the development of biodegradable plastics and ecofriendly alternatives.

Development Status: Technology Readiness Level 6 - Full System Prototype Built with Components Thoroughly Tested


Three U.S. patents pending


https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search/pad-tie


LA-UR-25-23941



LANL Tech Partnerships: Unlock the Innovative Potential


Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.


LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov.


Note: This is not a call for external services for the development of this technology.


https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology


https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search

Similar Contracts

NAICS: 541714
New
Federal
RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA) is seeking proposals under solicitation 75A50126R00002 to develop, obtain regulatory approval for, and procure approximately two million 2-PAM (600mg) autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. This effort supports the Strategic National Stockpile (SNS) and CHEMPACK Program. The contract is structured as a hybrid cost-plus-fixed-fee and firm-fixed-price instrument with an anticipated base performance period of up to 36 months and potential extension through options to a total duration of eight years. Key deliverables include late-stage clinical development, regulatory submission and approval, and large-scale manufacturing of autoinjectors, with production split across multiple CLINs totaling 2 million units. The solicitation is issued as a Statement of Objectives, requiring offerors to submit a comprehensive Statement of Work and Risk Mitigation Plan addressing program management, product development, supply chain logistics, and optional post-marketing commitments. Manufacturing and packaging must adhere to Good Manufacturing Practice regulations under 21 CFR Part 820, and all products must maintain strict temperature controls during transit, with ambient exposure logging required from the offeror’s validated facility until acceptance by the government at the ASPR/SNS location in Washington, D.C. All proposals must comply with mandatory eligibility criteria, including adherence to FAR and HHSAR clauses covering cost allowability, inspection, intellectual property, anti-kickback, and contingency fee restrictions. Offerors are required to complete SAM.gov representations and certifications, submit a detailed organizational chart identifying key personnel including a Program Director, Chief Scientific/Medical Officer, Manufacturing Lead, Regulatory Affairs Lead, and Project Manager, and demonstrate compliance with human subject protections under 45 CFR 46. Security requirements mandate layered physical controls, identification verification for personnel and visitors, and robust information and cyber security protocols encompassing access controls, intrusion detection, and encryption. Proposals must be submitted by July 30, 2026, and remain firm for 120 days. Evaluation will prioritize technical merit, past performance, and overall value over cost, with non-cost factors carrying significantly greater weight. Contract administration requires electronic invoice submissions via the Treasury IPP system to designated federal offices and strict adherence to documentation handling, packaging, and delivery protocols. The procurement is open to all qualified entities without set-aside restrictions
Barda - Aspr / Daappo / Barda Dcma

POSTED

4 days ago

DEADLINE

in 19 days
View Details